These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19795085)

  • 1. [Using parathyroid hormone 1-84 in the treatment of osteoporosis: presentation and comments of main clinical trial].
    Cesareo R; Napolitano C; Iozzino M; Romitelli F; Iarussi G; Scona M; De Rosa B
    Clin Ter; 2009; 160(4):307-10. PubMed ID: 19795085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anabolic treatment for osteoporosis: PTH treatment].
    Kaji H; Sugimoto T
    Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
    Wada S; Fukawa T; Kamiya S
    Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of osteoporosis with parathyroid hormone].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2008 Jan; 128(1):39-41. PubMed ID: 18183056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
    Nakamura T
    Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of osteoporosis with parathyroid hormone and teriparatide.
    Pleiner-Duxneuner J; Zwettler E; Paschalis E; Roschger P; Nell-Duxneuner V; Klaushofer K
    Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis.
    Nemeth EF
    IDrugs; 2008 Nov; 11(11):827-40. PubMed ID: 18988128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of parathyroid hormone in the management of osteoporosis.
    Rosen CJ
    Horm Res; 2005; 64 Suppl 2():81-5. PubMed ID: 16286779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Increase in bone mineral density and its effect on fracture risk].
    Sone T
    Clin Calcium; 2005 Apr; 15(4):625-9. PubMed ID: 15802775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
    Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
    J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of parathyroid hormone as a therapy for osteoporosis.
    Rubin MR; Bilezikian JP
    Int J Fertil Womens Med; 2002; 47(3):103-15. PubMed ID: 12081255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of parathyroid hormone for the treatment of osteoporosis.
    Morley P
    Expert Opin Drug Deliv; 2005 Nov; 2(6):993-1002. PubMed ID: 16296804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
    Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B
    Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.